At Palatin, we drive our culture with science. Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs.

Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye.

Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi ® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD). Robert oversees all of Palatin’s drug development programs as well as leads clinical operations.

The melanocortin system is mediated by a family of five related receptors that are essential to the body’s control of inflammation, immune response, metabolism, steroid hormone production, and sexual function. This expansive range of effects can …

CRANBURY, N.J., Jan. 28, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system (MCRS), today provided an update on anticipated corporate milestones expected to occur in calendar year ...

CRANBURY, N.J., Nov. 14, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced operating and financial results for its fiscal first quarter ended September 30, 2024.

Feb 28, 2024 · Palatin will host a conference call and audio webcast on February 28, 2024, at 8:30 a.m. Eastern Time to discuss the PL9643 Phase 3 clinical study results in greater detail. Individuals interested in listening to the conference call live can dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 295124.

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Oct 1, 2024 · Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.Palatin.com and …

In this section, you will find information regarding the financial highlights of Palatin. For your convenience, we provide a library of press releases, events, and webcasts, as well as prefiltered links to the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database.